Skip to content
Homepage
Author:
VALNEVA SE
Posted Date:
August 14, 2026
Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
VALNEVA SE
August 14, 2026
Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
VALNEVA SE
August 13, 2026
Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026
VALNEVA SE
July 22, 2026
Valneva Announces Successful Outcome of its Annual General Meeting
VALNEVA SE
June 25, 2026
